Sorafenib targets and inhibits several key kinases and receptors involved in cancer cell growth and survival, including RAF kinase, (Liu et al., 2006), VEGFR1-2, PDGFR, KIT, and RET proto-oncogene receptor tyrosine kinase (Wilhelm et al., 2008). Here, RET is linked to cancer.